191 related articles for article (PubMed ID: 20948318)
1. Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
Eulitt PJ; Park MA; Hossein H; Cruikshanks N; Yang C; Dmitriev IP; Yacoub A; Curiel DT; Fisher PB; Dent P
Cancer Biol Ther; 2010 Dec; 10(12):1290-305. PubMed ID: 20948318
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.
Hamed HA; Yacoub A; Park MA; Eulitt PJ; Dash R; Sarkar D; Dmitriev IP; Lesniak MS; Shah K; Grant S; Curiel DT; Fisher PB; Dent P
Mol Ther; 2010 Jun; 18(6):1130-42. PubMed ID: 20179672
[TBL] [Abstract][Full Text] [Related]
3. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.
Hamed HA; Das SK; Sokhi UK; Park MA; Cruickshanks N; Archer K; Ogretmen B; Grant S; Sarkar D; Fisher PB; Dent P
Cancer Biol Ther; 2013 Nov; 14(11):1039-49. PubMed ID: 24025359
[TBL] [Abstract][Full Text] [Related]
4. A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.
Park MA; Hamed HA; Mitchell C; Cruickshanks N; Dash R; Allegood J; Dmitriev IP; Tye G; Ogretmen B; Spiegel S; Yacoub A; Grant S; Curiel DT; Fisher PB; Dent P
Mol Pharmacol; 2011 Mar; 79(3):368-80. PubMed ID: 21119025
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype cancer terminator virus.
Sarkar S; Azab B; Quinn BA; Shen X; Dent P; Klibanov AL; Emdad L; Das SK; Sarkar D; Fisher PB
Curr Mol Med; 2014 Jan; 14(1):125-40. PubMed ID: 24236457
[TBL] [Abstract][Full Text] [Related]
6. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
7. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
[TBL] [Abstract][Full Text] [Related]
8. OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins.
Hamed HA; Yacoub A; Park MA; Eulitt P; Sarkar D; Dimitrie IP; Chen CS; Grant S; Curiel DT; Fisher PB; Dent P
Cancer Biol Ther; 2010 Apr; 9(7):526-36. PubMed ID: 20107314
[TBL] [Abstract][Full Text] [Related]
9. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
10. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
Azab B; Dash R; Das SK; Bhutia SK; Shen XN; Quinn BA; Sarkar S; Wang XY; Hedvat M; Dmitriev IP; Curiel DT; Grant S; Dent P; Reed JC; Pellecchia M; Sarkar D; Fisher PB
J Cell Physiol; 2012 May; 227(5):2145-53. PubMed ID: 21780116
[TBL] [Abstract][Full Text] [Related]
11. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells.
Dash R; Dmitriev I; Su ZZ; Bhutia SK; Azab B; Vozhilla N; Yacoub A; Dent P; Curiel DT; Sarkar D; Fisher PB
Cancer Gene Ther; 2010 Jul; 17(7):447-56. PubMed ID: 20150932
[TBL] [Abstract][Full Text] [Related]
12. mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling.
Yacoub A; Mitchell C; Lebedeva IV; Sarkar D; Su ZZ; McKinstry R; Gopalkrishnan RV; Grant S; Fisher PB; Dent P
Cancer Biol Ther; 2003; 2(4):347-53. PubMed ID: 14508103
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Lasithiotakis KG; Sinnberg TW; Schittek B; Flaherty KT; Kulms D; Maczey E; Garbe C; Meier FE
J Invest Dermatol; 2008 Aug; 128(8):2013-23. PubMed ID: 18323781
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
16. [Mda-7-carrying replication-defective adenovirus selectively kills hepatocellular carcinoma cells by facilitating release of proapoptotic protein from mitochondria].
Wang CJ; Peng ZH; Zheng JW; Chen K; Hu HY; Ji WW; Yu Y; Xue XB
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):649-53. PubMed ID: 19173903
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells.
Yacoub A; Liu R; Park MA; Hamed HA; Dash R; Schramm DN; Sarkar D; Dimitriev IP; Bell JK; Grant S; Farrell NP; Curiel DT; Fisher PB; Dent P
Mol Pharmacol; 2010 Feb; 77(2):298-310. PubMed ID: 19910452
[TBL] [Abstract][Full Text] [Related]
18. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.
Sarkar D; Lebedeva IV; Su ZZ; Park ES; Chatman L; Vozhilla N; Dent P; Curiel DT; Fisher PB
Cancer Res; 2007 Jun; 67(11):5434-42. PubMed ID: 17545625
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Hamed HA; Tavallai S; Grant S; Poklepovic A; Dent P
J Cell Physiol; 2015 Jan; 230(1):131-9. PubMed ID: 24911215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
